AzTrials
AzTrials

SARS-CoV InfectionMIOCOVIDNCT04959773

Muscle Weakness in COVID-19 Patients

An observational study of SARS-CoV Infection and Covid19, run by University of Pavia at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Although the Covid-19 infection mainly manifests itself with respiratory symptoms, as early as two months after the onset of the pandemic, the presence of other symptoms, including muscle ones, became clear. Read more about this study

Who is it for?
Ages 35 to 70 years
Conditions the study is for
SARS-CoV Infection, Covid19, Muscle Weakness
How many people
30 participants
Where
1 siteItaly
Study dates
15 Nov 2020to 30 Jan 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 70 years
  • All sexes
  • Adult, Older adult

Study population: Patients will be divided into three Groups : * COVID+ with exercise intolerance Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who suffer from muscle weakness after more than two months from infection. * COVID+ without exercise intolerance Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who recovered and came to their normal life. * CTRL Subjects of both sexes who do not have contracted SARS-COV-2 infection (swab negative and negative serological test (IgG)).

Who may be able to join

  • -

Who cannot join

  • presence of cardiovascular, neurological and metabolic disorders.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Azienda Ospedaliera

    Alessandria, AL, 15121

Other trials in Italy

About this study

Official title: Potential Mechanisms of Long-term Muscle Weakness and Decreased Exercise Tolerance in Patients Infected by SARS-COV-2

Although the Covid-19 infection mainly manifests itself with respiratory symptoms, as early as two months after the onset of the pandemic, the presence of other symptoms, including muscle ones, became clear. With the disappearance of the emergency and the advancement of knowledge, medium- and long-term effects have been reported at the level of different organs and systems. Many patients, after several months from infection, report intolerance to exercise and many suffer from pain and muscle weakness. No studies has been carried out on the muscular consequences of the infection and on their possible contribution to intolerance to exercise. Since skeletal muscle possesses the ACE2 receptor (Angiotensin converting enzyme 2) to which SARS-Cov-2 binds, it follows that the involvement of the skeletal muscle could be due not only to the secondary effects of the infection (e.g. reduced oxygen supply from persistent lung disease, perfusion defects from cardiovascular defects and vascular damage), but also to the direct action of virus (SARS-Cov-2 myositis).

The general purpose of the research is to quantify the spread of symptoms and signs of muscle weakness and pain among the patient population welcomed at the Cardiorespiratory Rehabilitation Department of the Alexandria Hospital which have been suffering from SARS-CoV-2, being discharged and healed for more than two months, and define the possible contribution of muscular modifications to exercise intolerance.

Read the detailed description

Exercise intolerance and muscle weakness have important consequences on the quality of life of healed patients and significant clinical implications: increased risk of falls and bone fractures, physical deconditioning and increased risk of chronic lung impairment and other diseases. Physical deconditioning and muscle weakness are, in fact, among the recognized risks of chronic pathologies. The identification of any covid-19 myopathy and its pathogenesis it would be of great importance to define adequate measures to counter it, for example through the prescription of physical exercise, limit the clinical consequences, improve the quality of life for many patients and decrease the cost for the National Health System. The present study aims to assess the frequency of easy fatigue, weakness and muscle pain in the population at the time of the onset of SARS-CoV-2 infection and after 2-3 months after healing. Moreover, as secondary outcome, it will evaluate the presence of objective signs of muscle involvement of theSARS-CoV-2 infections 2-3 months after recovery, quantifying the presence of myopathic structural changes and the causes of any muscle damage.

The study is a pilot single center clinical study, with non-pharmacological intervention, aimed at improve of clinical practice as an integral part of non-purpose health care industrial companies in accordance with the D.M. 17-12-2004 (No-Profit Trial).

The screening of eligible patients will be carried out by consulting the records paper-based clinics of patients belonging to the SSD Cardiorespiratory Rehabilitation of the Hospital of SS Antonio and Biagio and Cesare Arrigo in Alessandria. To eligible patients will be then submitted the information and consent document to participate in the study during the routine outpatient visits planned for these subjects. If following the explanations of the Investigator regarding the experimentation and evaluation of the document informative the patient decides to join the study and proceed with the following phases.

In-vivo physiological evaluation will be performed in suitable premises of the Center Interdepartmental Research Department of Biology and Sports Medicine of the University of Pavia equipped with the necessary equipment for first aid and in the presence of a doctor specialist in cardiology or related disciplines, with constant monitoring of vital parameters (arterial saturation, blood pressure and heart rate) and signal 12-lead electrocardiography. It will consist of an incremental cycle ergometer test until exhaustion; exhaustion will be defined by the patient's inability to maintain an adequate pedaling frequency, from reaching an equal heart rate value at least 85% of the predicted maximum heart rate or from a perception level fatigue (Borg scale) greater than 17. Patients will be asked before the assessment to become familiar with the instrumentation and with the researchers involved, by making briefs evidence. In the event that the patient / control subject complains of symptoms of fatigue, headache, dizziness, precordialgia or increased blood pressure during the exercise, this will be immediately suspended. In the presence of cardiovascular diseases or internist or in any case of serious general conditions the patient / control subject will not be enrolled in the study. Incremental testing and physiological assessments are used by several years from the research group of Physiology both on healthy volunteers and on patients with different pathologies (patients with neuromuscular pathologies, patients with heart failure, heart transplant patients, bronchopneumopathic patients) with no evidence of events adverse (Lanfranconi et al., 2006; Grassi et al., 2009; Marzorati et al., 2012a; Marzorati et al., 2012b; Mezzani et al., 2012; Mezzani et al., 2013; Grassi et al., 2020).

During the physiological assessment tests the following measurements will be performed:

  1. determination of pulmonary ventilation (VE), oxygen consumption (VO2) e of the production of carbon dioxide (VCO2) breath by breath by calorimetry indirect (Vyntus, Carefusion);
  2. detection of heart rate (HR) by electrocardiographic signal at 12 derivations
  3. determination of systolic (Gs) and cardiac (Q) output by impedance analysis trans-thoracic (Physioflow, Manatec Biomedical);
  4. measurements of the concentration of lactic acid ([La] b) in 20 microliters of capillary blood obtained from the earlobe or fingertip of the hand (Biosen C-line, EKF) at rest and after exercise;
  5. determination of oxygenation modifications of the vastus lateral muscle ([deoxy (Hb + Mb)]) estimated by quasi-infrared spectroscopy (NIRS, Portamon, Artinis). Moreover, immediately after a knee flexion-extension exercise a series of 10-18 short (5-10s) occlusions using a pressure cuff applied to the root of the thigh. To minimize the discomfort of the study participants two successive occlusions will be separated by a time interval of 5s-20s (for example 5s for occlusions from 1 to 5, 10s for occlusions from 6 to 10, 15-20s for occlusions from 11 to 15). A transient interruption of blood flow will be performed in order to achieve complete deoxygenation at the level of the investigated muscle (maximum time 3 minutes). The level-positioned NIRS probe of the vastus lateral muscle will allow to estimate the maximum oxidative capacity of the muscle.

Finally, to evaluate some muscular contractile properties, 3 maximum voluntary contractions (MVC) lasting 5 seconds will be required. Each contraction will be separated from the subsequent by an adequate recovery period.

Muscle biopsies will be performed at the Salvatore Maugeri IRCCS Foundation in Pavia (performed by Dr. Danilo Miotti) or at the Cardiorespiratory Rehabilitation SSD of the Alessandria Hospital (performed by Dr. Biagio Polla) through the concotome tool. Muscle biopsy used routinely for the diagnosis of pathologies muscles in neurology and, for decades now, for the study of physiological adaptations and pathological changes in human skeletal muscle. The human research projects of Muscle Plasticity Laboratory of the Department of Molecular Medicine used, with no evidence of adverse events, hundreds of biopsies obtained from healthy young subjects, sedentary and trained subjects, elderly subjects, subjects undergoing drug treatment (steroids), pneumopathic subjects in collaboration with ICS-Maugeri Pavia since 1994.

The analyzes on the biopsy material will be performed at the Department of Medicine Molecular of the University of Pavia, Human Physiology unit, Plasticity laboratory muscle, with the aim of evaluating the presence of a myopathic condition with modification quantitative and / or qualitative of skeletal muscle tissue. The laboratory has a vast experience in obtaining and analyzing human biopsy tissue having developed this approach among the first at an international level since 1996.

Medical subject headings
Severe Acute Respiratory Syndrome, COVID-19, Muscle Weakness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04959773
Study groupRoleWhat they receive
COVID+ with exercise intolerancePatients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who suffer from muscle weakness after more than two months from infection. The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion. general conditions.
COVID+ without exercise intolerancePatients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who recovered and came to their normal life. The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion.
Control healthy subjects (CTRL)Subjects of both sexes who do not have contracted SARS-COV-2 infection (swab negative and negative serological test (IgG)). The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Functional status

    Post-COVID-19 Functional Status scale

    Measured: at least 2 months after infection

  2. Perceived quality of life by EQ-5D-5L

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Measured: at least 2 months after infection

  3. Exercise intolerance

    Maximal oxygen consumption during incremental test

    Measured: at least 2 months after infection

  4. Muscle weakness

    Reduced muscle force during isometric contraction

    Measured: at least 2 months after infection

  5. Pulmonary function

    Spirometry and DLCO capacity

    Measured: at least 2 months after infection

Secondary outcomes (4)
  1. Muscle fatiguability

    Central and peripheral indexes of fatigue after an isotonic exercise

    Measured: at least 2 months after infection

  2. Histology and morphology of skeletal muscle

    The muscle sections will be stained with: 1) Hoechst nuclear dye for evaluating the presence of nucleated center cells and 2) Hematoxylin and Eosin (H\&E) for measuring the area of the cross section of the individual muscle fibers (CSA) and to reveal morphological alterations. The morphological analysis should first demonstrate the presence of atrophy of individual muscle fibers. From the morphological analysis it will also be possible to highlight the presence of inflammatory infiltrates, the presence of core nucleated cells and other signs of structural alteration.

    Measured: at least 2 months after infection

  3. Single muscle fiber mechanics

    Functional analyzes will be performed on single muscle fibers and on isolated myosin.

    The absolute isometric force (Po), the specific isometric force (Po / CSA) and the no-load shortening rate (Vo) of the individual muscle fibers will be determined with the slack test technique. The fibers, chemically deprived of the cell membrane through exposure to detergent (Triton X 100), will be stimulated by exposure to a solution containing Ca2 + and ATP ions. At the end of the functional experiment, the fibers will be collected and typed through the analysis of the isoform content of the myosin heavy chain (MHC).

    Measured: at least 2 months after infection

  4. Ex-vivo muscle oxidative function

    Through molecular analyzes it will be possible to investigate the mechanisms underlying the possible myopathic condition. The following molecular investigations will be performed with Real Time-PCR (RT-PCR) and Western Blot (WB) techniques: activation of the signaling pathways of synthesis and protein degradation (IGF-1 / Akt / mTOR; ubiquitin proteosome system, autophagy ); apoptosis; mitochondrial dynamics; redox state.

    Measured: at least 2 months after infection

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jul 2021
  2. Study start15 Nov 2020
  3. Primary completion15 May 2022
  4. Study completion30 Jan 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04959773
Sponsor's protocol ID
UPavia-MIOCOVID
Acronym
MIOCOVID
Status last verified
May 2023
First submitted
8 Apr 2021
Last updated
11 May 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of SARS-CoV Infection and Covid19, run by University of Pavia at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Functional status (time frame: at least 2 months after infection). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in